Fri, Oct 31, 2014, 8:21 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • lefty_rosenthal7 lefty_rosenthal7 Oct 24, 2012 9:25 AM Flag

    Aegerion Pharmaceuticals sole drug candidate, Lomitapide

    I have the Seeking Alpha article to thank for firing me up this morning.
    Sole Candidate? What the..... Imagine if the FDA poo pooed Aegerion, their stock would have been worth 2.00 a share if it had tapped out with the FDA.

    My other questions are where did this company come from thin air? I don't really remember this company being any serious competition to them? Also, who is their partner, do they have a big name Pharma helping them? The only thing I could gather was that Bristol Myers Squibb donated a molecule and this: Aegerion in-licensed lomitapide from Penn in 2006 and with the benefit of Dr. Rader’s wisdom and knowledge continued the development of lomitapide as a potential treatment for HoFH

    Wisdom and Knowledge? Isis came up with Mipo on their own. The only other similar story I can compare is maybe Cubist and CUBICIN®.

    This just doesn't seem right, Isis has an interesting approach to drug discovery for dozens of different drugs and Aegerion has one? Usually the FDA makes you cool your heels for awhile if you just have one drug. Mannkind comes to mind, so why didn't they do it to Aegerion is what I want to know.

    Wisdom and Knowledge.... hmmmm curious.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Got it ! isis has no drugs, get it ? Pipe line crap for 20 years, no drug, get it ? Crook at the wheel get it ?

    • "Usually the FDA makes you cool your heels for awhile if you just have one drug. Mannkind comes to mind, so why didn't they do it to Aegerion is what I want to know."

      Because Aegerion drug is more effective and does not have cancer issues.

      Stan kepts us in the dark about the cancer issue. Also, I do not recall anybody on this board taking about Aegerion having a competing drug to mipo even as early as April or even later of this year. As far as I know just everybody thought ISIS had the only drug for this disease and the liver issue was a side effect that was not going to be serious. I think had most investors were aware of these factors ISIS would never have gone over $10 a shre.

 
ISIS
46.06+0.18(+0.39%)Oct 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.